- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00807131
Effectiveness of Pharmaceutical Care on Primary Care Patients With Uncontrolled Hypertension (EPHACA)
Effectiveness of a Pharmaceutical Care Program on Primary Care Patients With Uncontrolled Hypertension- A Brazilian Multicenter RCT
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Inclusion and exclusion criteria: Potential hypertensive subjects aged above 18 years and and continuously receiving their medicines from the pharmacy are going to be identified through administrative data sources. They must take at least hydrochlorothiazide, and have no modifications on their hypertensive drug prescription on the last 2 months. Patients who have a serious psychiatric disorder or a severe cognitive impairment, blindness, pregnancy or secondary hypertension will be excluded. To be considered eligible, the patients should have a mean systolic and diastolic blood pressure above 140 mmHg and 90 mmHg at the screening visit if there were no COM morbidities associated, and above 130 mmHg and 80 mmHg for high-risk patients, using the validated Omron Hern-705-CP upper arm automated monitor.
Strategy/process by which participants/centres will be selected and recruited to the trial: Research assistants will invite the potential subjects when they attend the pharmacy to take their medicines or via telephone calls. By this moment, they will confirm eligibility and proceed the BP measures. If eligible for the study, the participant will receive all the trial explanations and the written informed consent will be obtained.
Randomization: The random allocation will be stratified by gender through a computer-generated sequence, individually for each centre. To maintain cancel allocation status, opaque, numbered and sealed envelopes will be adopted.
Interventions: Three different kinds of pharmacist services will be adopted, with growing complexity levels: drug dispensing, counseling and patient follow-up for 8 months. These methods are part of the Brazilian pharmaceutical care agreement, developed on the year of 2002, and will be compared with the pharmacy usual care. Seven pharmacists and 12 students were in charge of the pharmaceutical care program. All of them were trained in a 20 hour-course. Procedures details are written in a manual of operations, willing to standardize the interventions.
Outcomes: The primary outcomes are the BP differences between the one measured at 8-month follow-up and the baseline BP and the adherence, determined by 2 ways: a) measurement of plasma levels of hydrochlorothiazide, measured at the beginning and at the end of the study; b) drugs refill along the 8-months prior the randomization and during the 8-months of the trial. The occurrence of drug-related problems will be evaluated as a secondary outcome.
Blindness: Open-label study. Sample size: The study was design to enroll 304 patients equally distributed within the 4 centers, to provide 80% of statistical power to reject the null hypothesis and an error of 5% (two-tailed). Sampling size was calculated on the basis of a standard deviation of 10 mmHg, powered to detect clinically meaningful differences in mean changes of 5 mmHg between usual care and the intervention arms at 8-months follow-up, considering a 20% of drop-outs. Analyses will be conducted on intention-to-treat basis.
• Statistics: To assess for any differences among the intervention groups, the baseline characteristics will be compared performing Pearson χ2 test for categorical variables and F tests for continuous variables, and Fisher Exact test or Kruskal-Wallis if necessary. For the primary outcomes, the same tests will be applied. Analysis of covariance will be used when necessary.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil
- Mauro Silveira de Castro
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Potential hypertensive subjects aged above 18 years and and continuously receiving their medicines from the pharmacy are going to be identified through administrative data sources.
- They must take at least hydrochlorothiazide, and have no modifications on their hypertensive drug prescription on the last 2 months.
- To be considered eligible, the patients should have a mean systolic and diastolic blood pressure above 140 mmHg and 90 mmHg at the screening visit if there were no COM morbidities associated, and above 130 mmHg and 80 mmHg for high-risk patients.
Exclusion Criteria:
- Patients who have a serious psychiatric disorder or a severe cognitive impairment, blindness, pregnancy or secondary hypertension will be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: 1
Patient follow-up
|
Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences.
Its objectives are to improve the patient quality of life.
Autres noms:
|
Expérimental: 2
Counseling
|
The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
Autres noms:
|
Expérimental: 3
Drug dispensing
|
The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
Autres noms:
|
Comparateur actif: 4
pharmacy usual care
|
The patient receives no information about their medicines in the pharmacy, unless he asks for it.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Blood pressure
Délai: 8 months
|
8 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
adherence
Délai: 8 months
|
8 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Mauro Castro, PhD, Federal University of Health Science of Porto Alegre
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 402736/2005-2
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecrutementHypertension Essentielle | Hypertension, masquéTaïwan
-
University of Alabama at BirminghamTroy UniversityComplétéHypertension | Hypertension, résistante à la thérapie conventionnelle | Hypertension non contrôlée | Hypertension, blouse blancheÉtats-Unis
-
Vanderbilt University Medical CenterJohns Hopkins UniversityComplétéHypertension artérielle pulmonaire | Hypertension artérielle pulmonaire idiopathique | Hypertension artérielle pulmonaire associée | Hypertension artérielle pulmonaire héréditaireÉtats-Unis
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentInconnue
-
Centre Chirurgical Marie LannelongueInconnueHypertension pulmonaire thromboembolique chronique et hypertension artérielle pulmonaireFrance
-
Assistance Publique - Hôpitaux de ParisActif, ne recrute pasHypertension portale non cirrhotique intrahépatiqueFrance
-
University of Kansas Medical CenterRecrutementHypertension artérielle pulmonaire | Hypertension pulmonaire | Hypertension pulmonaire thromboembolique chronique | Hypertension pulmonaire due à une cardiopathie gauche | Hypertension pulmonaire, primaire, 4 | Hypertension pulmonaire, primaire, 2 | Hypertension pulmonaire, primaire, 3 | Hypertension... et d'autres conditionsÉtats-Unis
-
AstraZenecaComplétéHypertension artérielle (hypertension).
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldComplétéHypertension artérielle pulmonaire idiopathique | Hypertension pulmonaire thromboembolique chroniqueRoyaume-Uni
-
BayerComplété
Essais cliniques sur Patient follow-up
-
Shannon E. Sauer-ZavalaNational Institute of Mental Health (NIMH)Actif, ne recrute pasTrouble obsessionnel compulsif | Troubles anxieux | Trouble de stress post-traumatiqueÉtats-Unis
-
Shannon E. Sauer-ZavalaComplétéDépression | Trouble obsessionnel compulsif | Troubles anxieux | Trouble de stress post-traumatiqueÉtats-Unis
-
University of MichiganNational Institute on Drug Abuse (NIDA); Brown University; Pennington Biomedical... et autres collaborateursRecrutement
-
air up GmbHCitruslabsRecrutement
-
Johns Hopkins UniversityDonaghue Medical Research FoundationActif, ne recrute pas
-
University of MiamiThe Children's TrustComplétéLa dépression | Troubles anxieuxÉtats-Unis
-
Oregon Health and Science UniversityTexas A&M University; University of North Carolina, GreensboroActif, ne recrute pasActivité physiqueÉtats-Unis
-
Molnlycke Health Care ABRecrutementUlcère du pied diabétique | Plaie; Le pied | Ulcère veineux de la jambe | Blessures | Blessure de peau | Jambe blesséeÉtats-Unis
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecrutementMaladie critique | Enfant | Faiblesse acquise en unité de soins intensifs | Ulcère de pression nosocomialeÉtats-Unis
-
Daren K. HeylandNestlé; Queen's UniversityComplété